Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience
Wirawan Jeong, Peter Haywood, Naranie Shanmuganathan, Julian Lindsay, Karen Urbancic, Michelle R Ananda-Rajah, Sharon CA Chen, Ashish Bajel, David Ritchie, Andrew Grigg, John F Seymour, Anton Y Peleg, David CM Kong, Monica A Slavin
Journal of Antimicrobial Chemotherapy | OXFORD UNIV PRESS | Published : 2016
M. A. S. and S. C. A. C. have received grants from Pfizer, Merck Sharp and Dohme (MSD) and Gilead Sciences. D. C. M. K. has sat on advisory boards for Pfizer and MSD, and received financial/travel support unrelated to the current work from Roche, Pfizer, MSD and Gilead Sciences. K. U. has sat on an advisory board for MSD. M. R. A.-R. has received honoraria from Schering Plough and Gilead, grants from MSD and participated in an advisory board for MSD. A. Y. P. has been on an advisory board for MSD unrelated to the current work. P. H. has sat on an advisory board for Amgen. All other authors: none to declare.